What can be added to Reglan (metoclopramide) and Zofran (ondansetron) for a patient with chemotherapy-induced nausea and vomiting (CINV)?

Adding to Reglan and Zofran for CINV

Add dexamethasone as the essential third agent to your Reglan (metoclopramide) and Zofran (ondansetron) regimen, and strongly consider adding an NK1 receptor antagonist (aprepitant, fosaprepitant, rolapitant, or netupitant/palonosetron combination) for optimal CINV control, particularly for highly or moderately emetogenic chemotherapy. 1

Primary Addition: Dexamethasone (Corticosteroid)

Dexamethasone is the most critical addition and should be included in virtually all CINV prophylaxis regimens. 1

• Dosing for highly emetogenic chemotherapy: Dexamethasone 12 mg PO/IV on day 1 (when combined with NK1 antagonist), followed by 8 mg once or twice daily on days 2-4 1
• Dosing for moderately emetogenic chemotherapy: Dexamethasone 12 mg PO/IV on day 1, with continuation on days 2-3 as needed 1
• Mechanism: Dexamethasone combined with ondansetron is significantly more effective than ondansetron monotherapy for both acute and delayed emesis 1, 2

Secondary Addition: NK1 Receptor Antagonists

For patients receiving highly or moderately emetogenic chemotherapy, adding an NK1 receptor antagonist provides superior control of both acute and delayed CINV compared to 5-HT3 antagonist plus dexamethasone alone. 1, 3

NK1 Antagonist Options:

Aprepitant (oral):

• 125 mg PO on day 1 (before chemotherapy), then 80 mg PO on days 2-3 1
• Increases complete response rates from 68-78% to 83-89% for acute emesis and from 47-56% to 68-75% for delayed emesis when added to ondansetron plus dexamethasone 1, 3

Fosaprepitant (IV):

• 150 mg IV on day 1 only (eliminates need for days 2-3 dosing) 1
• Non-inferior to 3-day oral aprepitant regimen 1

Rolapitant (oral):

• 180 mg PO once on day 1 only 1
• Extended half-life; should not be administered at intervals less than 2 weeks 1

Netupitant/palonosetron combination (NEPA):

• 300 mg netupitant/0.5 mg palonosetron PO once on day 1 1, 4
• Combines NK1 antagonist with second-generation 5-HT3 antagonist in single dose 4

Evidence Strength for NK1 Antagonists:

• Highly emetogenic chemotherapy: NK1 antagonists added to standard therapy (5-HT3 antagonist + dexamethasone) significantly improve complete response rates for both acute and delayed emesis 1, 3
• Moderately emetogenic chemotherapy: NK1 antagonists improve complete response rates from 43% to 51% over 120 hours post-chemotherapy 1
• Delayed emesis: NK1 antagonists provide particularly significant benefit for delayed nausea and vomiting (days 2-5), where they are most needed 1

Alternative Addition: Olanzapine

Olanzapine 10 mg PO once daily (days 1-4) combined with palonosetron and dexamethasone represents an alternative highly effective regimen, particularly when NK1 antagonists are unavailable or contraindicated. 1

• Olanzapine 10 mg PO on day 1 with palonosetron 0.25 mg IV and dexamethasone 20 mg IV, then olanzapine 10 mg PO daily on days 2-4 1
• Consider 5 mg dose for elderly or over-sedated patients 1

Critical Prescribing Considerations

Drug Interactions with NK1 Antagonists:

Aprepitant is a CYP3A4 substrate, moderate inducer, and moderate inhibitor, requiring dexamethasone dose reduction by approximately 50% when used together. 1, 5

• When aprepitant is added, reduce dexamethasone from 20 mg to 12 mg on day 1 1
• Aprepitant contraindicated with pimozide, terfenadine, astemizole, or cisapride 1

Regimen Selection Algorithm:

For highly emetogenic chemotherapy (e.g., cisplatin ≥50 mg/m²):

1. Triple therapy is mandatory: 5-HT3 antagonist (ondansetron) + NK1 antagonist + dexamethasone 1
2. If NK1 antagonist unavailable, use olanzapine-based regimen 1

For moderately emetogenic chemotherapy (e.g., carboplatin, oxaliplatin, doxorubicin, cyclophosphamide):

1. Minimum: 5-HT3 antagonist + dexamethasone 1
2. Add NK1 antagonist for patients with additional risk factors or previous treatment failure 1

For breakthrough emesis despite prophylaxis:

1. Add dopamine antagonist (metoclopramide or prochlorperazine) to existing regimen 6, 7
2. Consider escalating to NK1 antagonist-containing regimen for next cycle if not already using 1

Common Pitfalls to Avoid:

• Do not use ondansetron monotherapy for moderate-to-high emetogenic chemotherapy—combination with dexamethasone is essential 6, 5, 7
• Do not exceed ondansetron 16 mg single IV dose due to QT prolongation risk 5, 7
• Do not use ondansetron 32 mg IV single dose—this is no longer recommended due to cardiac safety concerns 5
• Do not forget to reduce dexamethasone dose by 50% when combining with aprepitant due to CYP3A4 interactions 1, 5

Adjunctive Agents:

Lorazepam 0.5-2 mg PO/IV/sublingual every 6 hours as needed can be added for anticipatory nausea or anxiety 1, 6

H2 blocker or proton pump inhibitor may be added for gastric protection, particularly with corticosteroid use 1